Christopher Anzalone's most recent trade in Arrowhead Pharmaceuticals Inc. was a trade of 50,800 Common Stock done at an average price of $11.5 . Disclosure was reported to the exchange on April 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 11.49 per share. | 09 Apr 2025 | 50,800 | 3,921,255 (3%) | 0% | 11.5 | 583,692 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 10.87 per share. | 09 Apr 2025 | 50,000 | 3,972,055 (3%) | 0% | 10.9 | 543,500 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 9.93 per share. | 09 Apr 2025 | 35,305 | 4,027,072 (3%) | 0% | 9.9 | 350,579 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 10.75 per share. | 09 Apr 2025 | 3,400 | 4,023,672 (3%) | 0% | 10.8 | 36,550 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 11.76 per share. | 09 Apr 2025 | 1,617 | 4,022,055 (3%) | 0% | 11.8 | 19,016 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Mar 2025 | 340,000 | 4,113,802 (4%) | 0% | 0 | Common Stock | |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 15.07 per share. | 13 Mar 2025 | 51,425 | 4,062,377 (3%) | 0% | 15.1 | 774,975 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.03 per share. | 03 Mar 2025 | 166,667 | 3,907,135 (3%) | 0% | 18.0 | 3,005,006 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 166,667 | 185,059 | - | - | Stock Option (right to buy Common Stock) | |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.75 per share. | 03 Mar 2025 | 166,667 | 3,940,469 (3%) | 0% | 7.7 | 1,291,669 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.75 per share. | 03 Mar 2025 | 133,333 | 4,073,802 (4%) | 0% | 7.8 | 1,033,331 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 17.02 per share. | 03 Mar 2025 | 133,333 | 3,773,802 (3%) | 0% | 17.0 | 2,269,328 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 133,333 | 51,726 | - | - | Stock Option (right to buy Common Stock) | |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 20.10 per share. | 07 Feb 2025 | 9,550 | 3,773,802 (3%) | 0% | 20.1 | 191,955 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 19.05 per share. | 02 Jan 2025 | 11,520 | 3,764,252 (3%) | 0% | 19.1 | 219,456 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 19.59 per share. | 23 Dec 2024 | 12,563 | 3,775,772 (3%) | 0% | 19.6 | 246,109 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 100,000 | 3,788,335 (3%) | 0% | 0 | Common Stock | |
| Arrowhead Pharmaceuticals Inc | Anzalone Christopher | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 20.52 per share. | 18 Dec 2024 | 12,653 | 3,702,394 (3%) | 0% | 20.5 | 259,640 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 21.74 per share. | 18 Dec 2024 | 8,260 | 3,694,134 (3%) | 0% | 21.7 | 179,572 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Anzalone Christopher | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 22.12 per share. | 18 Dec 2024 | 5,799 | 3,688,335 (3%) | 0% | 22.1 | 128,274 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Anzalone Christopher | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2024 | 57,499 | 351,726 | - | - | Stock Option (right to buy) | |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.54 per share. | 31 Jan 2024 | 57,499 | 3,772,547 (3%) | 0% | 14.5 | 836,035 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 32.16 per share. | 31 Jan 2024 | 37,769 | 3,734,778 (3%) | 0% | 32.2 | 1,214,651 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 32.71 per share. | 31 Jan 2024 | 19,730 | 3,715,048 (3%) | 0% | 32.7 | 645,368 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 31.25 per share. | 02 Jan 2024 | 5,318 | 3,715,048 (3%) | 0% | 31.3 | 166,188 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 30.74 per share. | 02 Jan 2024 | 4,634 | 3,720,366 (3%) | 0% | 30.7 | 142,449 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Anzalone Christopher | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 28.54 per share. | 20 Dec 2023 | 12,000 | 3,725,000 (3%) | 0% | 28.5 | 342,480 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.01 per share. | 03 May 2023 | 54,928 | 3,816,266 (3%) | 0% | 2.0 | 110,405 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 39.14 per share. | 03 May 2023 | 54,928 | 3,761,338 (3%) | 0% | 39.1 | 2,149,882 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2023 | 54,928 | 516,980 | - | - | Stock Option (right to buy) | |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2023 | 50,000 | 466,980 | - | - | Stock Option (right to buy) | |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.01 per share. | 03 May 2023 | 50,000 | 3,811,338 (3%) | 0% | 2.0 | 100,500 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 40.02 per share. | 03 May 2023 | 25,992 | 3,761,338 (3%) | 0% | 40.0 | 1,040,200 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 38.97 per share. | 03 May 2023 | 24,008 | 3,787,330 (3%) | 0% | 39.0 | 935,592 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 234,025 | 3,720,714 (3%) | 0% | 0 | Common Stock | |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 18,375 | 3,486,689 (3%) | 0% | 0 | Common Stock | |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.77 per share. | 27 Sep 2022 | 39,082 | 3,469,856 (3%) | 0% | 30.8 | 1,202,553 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.21 per share. | 27 Sep 2022 | 1,542 | 3,468,314 (3%) | 0% | 31.2 | 48,126 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jul 2022 | 551,197 | 3,508,938 (3%) | 0% | 0 | Common Stock | |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2022 | 2,501 | 612,532 | - | - | Stock Option (right to buy Common Stock) | |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.54 per share. | 07 Jul 2022 | 2,501 | 4,060,135 (3%) | 0% | 14.5 | 36,365 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2022 | 146,388 | 615,033 | - | - | Stock Option (right to buy Common Stock) | |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.19 per share. | 11 Feb 2022 | 146,388 | 4,204,022 (4%) | 0% | 5.2 | 759,754 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 50.90 per share. | 11 Feb 2022 | 61,482 | 4,059,534 (3%) | 0% | 50.9 | 3,129,434 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 52.28 per share. | 11 Feb 2022 | 42,153 | 4,121,016 (4%) | 0% | 52.3 | 2,203,759 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 53.11 per share. | 11 Feb 2022 | 40,853 | 4,163,169 (4%) | 0% | 53.1 | 2,169,703 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 50.51 per share. | 11 Feb 2022 | 1,900 | 4,057,634 (3%) | 0% | 50.5 | 95,969 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2022 | 800,000 | 4,045,828 (3%) | 0% | 0 | Common Stock | |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2021 | 11,806 | 773,227 | - | - | Stock Option (right to buy Common Stock) | |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.19 per share. | 23 Dec 2021 | 11,806 | 3,245,828 (3%) | 0% | 5.2 | 61,273 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 65.57 per share. | 20 Oct 2021 | 44,170 | 3,284,852 (3%) | 0% | 65.6 | 2,896,227 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 66.23 per share. | 20 Oct 2021 | 15,000 | 3,329,022 (3%) | 0% | 66.2 | 993,450 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 66.09 per share. | 20 Oct 2021 | 5,830 | 3,279,022 (3%) | 0% | 66.1 | 385,305 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 28 Dec 2020 | 1,126 | 2,544,621 (2%) | 0% | 0 | Common Stock | |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2020 | 28,274 | 800,033 | - | - | Common Stock (right to buy) | |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.15 per share. | 18 Dec 2020 | 28,274 | 2,545,747 (2%) | 0% | 6.1 | 173,885 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.75 per share. | 18 Dec 2020 | 12,236 | 2,517,473 (2%) | 0% | 4.8 | 58,121 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2020 | 12,236 | 828,307 | - | - | Common Stock (right to buy) | |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.01 per share. | 08 Dec 2020 | 38,676 | 2,543,913 (2%) | 0% | 2.0 | 77,739 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2020 | 38,676 | 840,543 | - | - | Stock Option (right to buy) | |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.27 per share. | 08 Dec 2020 | 16,726 | 2,527,187 (2%) | 0% | 67.3 | 1,125,158 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 67.97 per share. | 08 Dec 2020 | 16,324 | 2,505,237 (2%) | 0% | 68.0 | 1,109,542 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.01 per share. | 08 Dec 2020 | 16,324 | 2,521,561 (2%) | 0% | 2.0 | 32,811 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2020 | 16,324 | 879,219 | - | - | Stock Option (right to buy) | |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 69.80 per share. | 08 Dec 2020 | 12,067 | 2,515,120 (2%) | 0% | 69.8 | 842,277 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 70.87 per share. | 08 Dec 2020 | 5,880 | 2,509,240 (2%) | 0% | 70.9 | 416,716 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 71.61 per share. | 08 Dec 2020 | 4,003 | 2,505,237 (2%) | 0% | 71.6 | 286,655 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 58.16 per share. | 23 Oct 2020 | 87,728 | 2,517,509 (2%) | 0% | 58.2 | 5,102,260 | Common Stock |
| Arrowhead Pharmaceuticals Inc | Christopher Anzalone | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 58.57 per share. | 23 Oct 2020 | 12,272 | 2,505,237 (2%) | 0% | 58.6 | 718,771 | Common Stock |